BV-AVD in Patients With Newly-Diagnosed, Early Stage, Bulky Hodgkin Lymphoma Using a PET-adapted and MTV-guided Approach

Summary

The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease. BV is a type of drug called an antibody-drug conjugate (ADC). ADCs are a substance made up of a monoclonal antibody chemically linked to a drug. Antibodies are proteins made by the immune system to fight infections and other possible harms to the body. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer cells. The linked drug enters these cells and kills them without harming other cells. Researchers think BV may be an effective treatment for this type of cancer because the drug targets cells that have CD30, which play a role in cancer cell growth. By destroying these cells, BV may help slow or stop the growth of the cancer. AVD (doxorubicin, vinblastine, and dacarbazine) is a treatment regimen that works by stopping the growth of cancer cells, either by killing the cells or by stopping them from dividing. The researchers think that BV in combination with AVD may work better than AVD alone to slow or stop the growth of the cancer.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Brentuximab vedotin

  Brentuximab vedotin will be administered at 1.2 mg/kg IV on days 1 and 15 of each 28-day cycle

• Drug
  Doxorubicin

  Doxorubicin 25 mg/m\^2 IV

• Drug
  Vinblastine

  Vinblastine 6 mg/m\^2 IV

• Drug
  Dacarbazine

  Dacarbazine 375 mg/m\^2 IV on days 1 and 15 of each 28-day cycle

• Drug
  Pembrolizumab

  Pembrolizumab will be administered at 200 mg IV (flat) on day 1

• Drug
  Gemcitabine

  Gemcitabine 1000 mg/m\^2 IV (days 1 an

• Drug
  Vinorelbine

Locations (8)